Literature DB >> 9579238

Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects.

S Rittig1, A R Jensen, K T Jensen, E B Pedersen.   

Abstract

OBJECTIVE: The effect of food ingestion on the gastrointestinal absorption and antidiuretic action of oral desmopressin. An oral preparation of desmopressin, a synthetic analogue of vasopressin, has recently become available for clinical use.
DESIGN: A randomized, single-blind, crossover study with four treatment arms. Day A, no meal + placebo; B, no meal + 400 micrograms oral desmopressin; C, standard meal + 400 micrograms oral desmopressin; D, standard meal + 400 micrograms oral desmopressin after 1.5 hours. Plasma desmopressin was measured every 15-30 minutes for 6 hours after drug intake. An intravenous hydration regimen was employed on each study day.
SUBJECTS: Sixteen healthy, non-smoking, mean aged 20-35 years (mean 27.8 years). MEASUREMENTS: Plasma desmopressin concentrations were measured throughout each study day to calculate the area under the desmopressin plasma-concentration-time curve to infinity (AUCinf), the maximum plasma desmopressin concentration (Cmax), the time at which Cmax was reached (Tmax) and the time at which plasma desmopressin was first detected (Tlag). Urine volume, urine osmolality and plasma sodium concentrations were also measured at specified times on each study day.
RESULTS: The total absorption of oral desmopressin, reflected by the AUCinf, was significantly higher when taken during the fasting state (day B) compared with its administration with or 1.5 hours after a standard meal (days C and D). In addition, Cmax was higher and both Tmax and Tlag were shorter on day B compared with days C and D. No effect of food ingestion was observed on the pharmacodynamics of oral desmopressin: urine volume was decreased and urine osmolality was increased to similar extents on all active treatment days (B, C and D). No significant reductions in plasma sodium concentrations (a safety parameter) was observed during the trial.
CONCLUSIONS: The gastrointestinal absorption of desmopressin is reduced and delayed if administered with or 1.5 hours after a meal. This decreased absorption of desmopressin did not have an impact on the antidiuretic action of the drug since all treatment regimens elicted a maximal response. It is possible that administration of desmopressin in the fasting state may prolong its duration of action.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579238

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  16 in total

1.  Indirect-response modeling of desmopressin at different levels of hydration.

Authors:  T Callréus; J Odeberg; S Lundin; P Höglund
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

2.  Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years.

Authors:  Asa Rembratt; Charlotte Graugaard-Jensen; Thomas Senderovitz; Jens Peter Norgaard; Jens Christian Djurhuus
Journal:  Eur J Clin Pharmacol       Date:  2004-06-09       Impact factor: 2.953

Review 3.  Desmopressin: in adults with nocturia.

Authors:  Risto S Cvetković; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis.

Authors:  Pauline De Bruyne; Ann De Guchtenaere; Charlotte Van Herzeele; Ann Raes; Jo Dehoorne; Piet Hoebeke; Erik Van Laecke; Johan Vande Walle
Journal:  Eur J Pediatr       Date:  2013-08-30       Impact factor: 3.183

5.  Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues.

Authors:  Johan Van de Walle; Charlotte Van Herzeele; Ann Raes
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

6.  Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children.

Authors:  Robin Michelet; Lien Dossche; Pauline De Bruyne; Pieter Colin; Koen Boussery; Johan Vande Walle; Jan Van Bocxlaer; An Vermeulen
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

7.  Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.

Authors:  Robin Michelet; Lien Dossche; Charlotte Van Herzeele; Jan Van Bocxlaer; An Vermeulen; Johan Vande Walle
Journal:  Eur J Clin Pharmacol       Date:  2017-12-03       Impact factor: 2.953

8.  An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?

Authors:  Robin Michelet; Lien Dossche; Charlotte Van Herzeele; Pauline De Bruyne; Elke Gasthuys; Jan Van Bocxlaer; Johan Vande Walle; An Vermeulen
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

Review 9.  Pharmacotherapy for nocturia in the elderly patient.

Authors:  Ragnar Asplund
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  Solid lipid particles for oral delivery of peptide and protein drugs III - the effect of fed state conditions on the in vitro release and degradation of desmopressin.

Authors:  Philip C Christophersen; Dimple Vaghela; Anette Müllertz; Mingshi Yang; Hanne M Nielsen; Huiling Mu
Journal:  AAPS J       Date:  2014-05-30       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.